Compare Organon & Co. Common Stock (OGN) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Redwire Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Redwire Corporation trades at $8.43 (market cap $2.29B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Redwire Corporation for 18 Days on average.
| OGN | RDW | |
|---|---|---|
Market Cap | $3.62B | $2.29B |
Volume | 2,892,999 | 9,800,070 |
Sector | Health | Industrials |
52-Week High | $13.81 | $25.90 |
52-Week Low | $5.70 | $5.06 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.04B | $1.82B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Redwire Corporation (RDW) trades at $9.16, down 0.65% on the day, showing bearish technical signals despite recent contract wins. The company reported strong revenue growth with Q2 2026 showing 89.6% year-over-year increase, but continues to post significant losses with a net income margin of -57.26%. Recent developments include a $981 million Space Force contract award and partnerships with Honda and Sophia Space for orbital infrastructure projects.
While analyst consensus remains bullish with an 80% buy rating and $14.88 price target, the stock faces substantial execution risks amid persistent losses and negative cash flow from operations. The company's growth trajectory depends heavily on successful contract execution and SpaceX's Starship development, making this a high-risk, high-potential investment in the emerging space economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
